698-P: Moderate-to-Vigorous Physical Activity Associated with Microalbuminuria in Type 2 Diabetes: A Cross-Sectional Study

Background and Aims: Moderate-to-vigorous physical activity (MVPA) could reduce both the incidences of type 2 diabetes in the general population and of cardiovascular events in patients with type 2 diabetes. Several guidelines have indicated that patients with diabetes were advised to perform MVPA for >150 min per week. Recent studies have not shown apparent harmful effects of physical activity in patients with diabetic nephropathy. However, the association between physical activity and microalbuminuria remains unknown. Thus, MVPA time was evaluated using an accelerometer, and its association with microalbuminuria was investigated in the present cross-sectional study. Materials and Methods: MVPA time was measured using a tri-axial accelerometer ActiGraph (ActiGraph Corp., Pensacola, Florida). Patients with diabetes were instructed to use the accelerometer for 7 days, except while bathing and sleeping. MVPA was defined as >1,952 counts per min. The association between MVPA and log urine albumin-to-creatinine ratio (UACR) was assessed using the linear regression model. In the multivariate model, age, gender, height, body weight, grip strength, blood pressure, sedentary time, hemoglobin A1c, estimated glomerular filtration rate, total cholesterol, insulin use, and ACE/ARB inhibitor use were used as covariates. Results: Among 236 patients (157 men, 66.5%), the mean age, body mass index, hemoglobin A1c, daily MVPA, and median UACR were 65.5 ± 9.3 years, 23.3 ± 3.4 kg/m2, 7.4% ± 1.0%, 27.2 ± 24.5 min, and 11.8 mg/gCr, respectively. Approximately 7.7% of patients had microalbuminuria of >300 mg/gCr. Log UACR was associated with daily MVPA in the univariate (r = −0.17, P = 0.010) and multivariate models (s = −0.14, P = 0.046). Conclusion: MVPA time was associated with UACR in Japanese patients with type 2 diabetes. Although patients with severe diabetic nephropathy have low physical activity levels, patients included in this study had no or mild nephropathy. Disclosure T. Osaka: None. Y. Hashimoto: None. T. Senmaru: None. E. Ushigome: None. M. Asano: None. M. Hamaguchi: None. M. Yamazaki: None. M. Fukui: None.